AMRX - Amneal Pharmaceuticals, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
6.89
+0.02 (+0.29%)
As of 2:05PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.87
Open6.86
Bid6.89 x 1300
Ask6.90 x 900
Day's Range6.77 - 7.01
52 Week Range6.77 - 24.48
Volume923,852
Avg. Volume991,079
Market Cap2.059B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
    PR Newswire2 days ago

    AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

    NEW ORLEANS , June 14, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...

  • Business Wire11 days ago

    Amneal Pharmaceuticals to Present at Upcoming Investor Conferences

    Amneal Pharmaceuticals, Inc. today announced that members of management will participate at the following upcoming investor conferences:

  • Business Wirelast month

    AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (AMRX). For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products. The Company has been sued in a securities class action lawsuit for failing to disclose material information to shareholders, violating federal securities laws, which is ongoing.

  • Business Wirelast month

    Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

    Amneal Pharmaceuticals, Inc. today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m.

  • PR Newswirelast month

    AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm

    NEW YORK , May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") ...

  • Business Wirelast month

    Amneal Reports First Quarter 2019 Financial Results

    ‒ Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS of $0.14 ‒

  • Business Wire2 months ago

    Amneal to Report First Quarter 2019 Results on May 9, 2019

    Amneal Pharmaceuticals, Inc. will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on May 9, 2019.

  • Business Wire2 months ago

    Amneal Names Pradeep Bhadauria as Chief Scientific Officer

    Amneal Pharmaceuticals, Inc. (AMRX), today announced that the company has appointed Pradeep Bhadauria as Chief Scientific Officer (CSO), effective immediately. Pradeep brings significant R&D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies.

  • PR Newswire3 months ago

    Amneal Announces Agreement with Zentiva to Divest Creo Pharma

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company's commercial operations in the United Kingdom. "We believe that the value created by our commercial operations in the UK will be better maximized by Zentiva, which will gain additional products and enhanced competitive market share position as a result of this transaction," said Rob Stewart, President and CEO of Amneal.

  • Amneal Announces Launch of Rivastigmine Transdermal System
    PR Newswire3 months ago

    Amneal Announces Launch of Rivastigmine Transdermal System

    BRIDGEWATER, N.J., March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has launched its generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year. "We are pleased to have received approval on and launched the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," said Rob Stewart, President and CEO of Amneal.

  • PR Newswire3 months ago

    Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference

    BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare ...

  • PR Newswire4 months ago

    Amneal Reports Fourth Quarter And Full Year 2018 Financial Results

    ‒ Q4 2018 Net Revenue of $498 Million ; GAAP Loss per share of $0.07 ; Combined Adjusted Diluted EPS(1) of $0.33 ‒ ‒ Full Year 2018 Net Revenue of $1.66 Billion ; GAAP Loss per share of $0.16 ; Combined ...

  • PR Newswire5 months ago

    Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019

    - Announces 2019 Quarterly Earnings Dates - BRIDGEWATER, N.J. , Jan. 24, 2019 /PRNewswire/ --  Amneal Pharmaceuticals, Inc. (NYSE: AMRX)  announced today that the Company will release its fourth quarter ...

  • Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer
    PR Newswire5 months ago

    Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer

    BRIDGEWATER, N.J., Jan. 22, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) today announced that it has appointed Todd P. Branning as Senior Vice President and Chief Financial Officer, effective today. Mr. Branning will be responsible for leading Amneal's global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Corporate Communications, and Information Technology.

  • Amneal Announces Approval of Rivastigmine Transdermal System
    PR Newswire5 months ago

    Amneal Announces Approval of Rivastigmine Transdermal System

    BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has received FDA approval for a generic version of Exelon® Patch  (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company is planning to commercialize its Rivastigmine Transdermal System shortly. "We are pleased to receive approval on the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," said Rob Stewart, President and CEO of Amneal.

  • PR Newswire5 months ago

    Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary

    BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) today announced that it has appointed David A. Buchen to the newly expanded role of Senior Vice President, Chief Legal Officer and Corporate Secretary, reporting to President and Chief Executive Officer Robert Stewart. Mr. Buchen brings more than 25 years of experience in the pharmaceutical industry, with notable expertise driving corporate value creation through world-class legal strategies supporting corporate securities, IP, anti-trust, employment, litigation and Mergers & Acquisitions (M&A).

  • PR Newswire6 months ago

    Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

    BRIDGEWATER, N.J. , Dec. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 37 th Annual J.P. Morgan Healthcare Conference ...

  • Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
    PR Newswire7 months ago

    Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference

    BRIDGEWATER, N.J. , Nov. 21, 2018 /PRNewswire/ --  Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Piper Jaffray Healthcare Conference in New York, NY , on Tuesday, ...

  • Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
    PR Newswire7 months ago

    Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st

    BRIDGEWATER, N.J., Nov. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodium tablets from Lannett beginning December 1, 2018 through March 23, 2019, ahead of when the Company's previously announced 10-year Levothyroxine distribution agreement with Jerome Stevens begins on March 23, 2019. "Today's announcement benefits customers and patients by ensuring a smooth transition for this important medication," said Rob Stewart, President and CEO of Amneal.

  • Amneal Announces Solid Third Quarter 2018 Financial Results
    PR Newswire7 months ago

    Amneal Announces Solid Third Quarter 2018 Financial Results

    ‒ Net Revenue of $476 Million ; Diluted EPS of $0.05 ; Adjusted Diluted EPS of $0.28 ‒ ‒ Integration of Amneal and Impax Nearing Completion; On Track to Achieve More Than $200 Million in Cost Synergies ...

  • Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
    PR Newswire8 months ago

    Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months

    BRIDGEWATER, N.J., Oct. 25, 2018 /PRNewswire/ -- Impax Laboratories LLC (the "Company"), a subsidiary of Amneal Pharmaceuticals, Inc. (AMRX), today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is extending the expiration dates for certain lots of its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg, the authorized generic of Adrenaclick®. Based on the medical necessity of epinephrine auto-injector and to assist with any shortages, the expiration date for specific lots will be increased from 18 months to 20 months. To help ensure patient safety, the FDA advises that supplies of epinephrine injection, USP auto-injector should have been – and should continue to be – stored as labeled.

  • Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa
    PR Newswire8 months ago

    Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa

    BRIDGEWATER, N.J. , Oct. 24, 2018 /PRNewswire/ --  Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that a patent protecting IPX203 has been issued by the United States Patent and Trademark Office. ...

  • ACCESSWIRE8 months ago

    These 3 Stocks Are Moving Higher This Month

    Believe it or not, there are stocks focusing on healthcare that have managed to hit new highs this month including Premier Health Group, Inc. (PHGRF)(PHGI.CN), Titan Pharmaceuticals (TTNP), and Amneal Pharmaceuticals Inc. (AMRX). Premier Health Group, Inc. (PHGRF)(PHGI.CN), has managed to hit trading levels as high as CAD$0.88 this month. The company announced that just this week its common shares that are traded on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol "PHGRF," are now Depository Trust Company eligible.

  • Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
    PR Newswire8 months ago

    Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension

    BRIDGEWATER, N.J. , Oct. 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Onfi ®  (clobazam) tablets, 10 mg ...

  • Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
    PR Newswire8 months ago

    Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch

    BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ --  Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU ®  (carmustine) for injection, ...